Piper Sandler Downgrades Abiomed to Neutral, Raises Price Target to $380
Piper Sandler analyst Matt O'Brien downgrades Abiomed (NASDAQ:ABMD) from Overweight to Neutral and raises the price target from $350 to $380.
Abiomed Completes All Impella Post-Approval Studies For High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock And Right Heart Failure
Abiomed (NASDAQ:ABMD) announces the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps. The
Mizuho Initiates Coverage On Abiomed with Buy Rating, Announces Price Target of $300
Mizuho analyst Anthony Petrone initiates coverage on Abiomed (NASDAQ:ABMD) with a Buy rating and announces Price Target of $300.
Abiomed Highlights Multi-Society Study Of Impella-supported Patients
Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Morgan Stanley Maintains Underweight on Abiomed, Lowers Price Target to $235
Morgan Stanley analyst David Lewis maintains Abiomed (NASDAQ:ABMD) with a Underweight and lowers the price target from $275 to $235.
Abiomed Q4 EPS $1.16 Beats $1.09 Estimate, Sales $270.00M Beat $267.67M Estimate
Abiomed (NASDAQ:ABMD) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.09 by 6.42 percent. This is a 6.45 percent decrease over earnings of $1.24 per share from the same
Abiomed Highlights First Patient Successfully Implanted With Impella Bridge-To-Recovery
Abiomed (NASDAQ:ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR) as part of the heart pump’s U.S. Food and Drug Administration (FDA) Early
Markets Rise Despite Another New 2-Year High For US 10-Year Treasury Note
U.S. indices traded higher Tuesday on continued volatility as traders assess Fed policy outlook, rising Treasury yields and quarterly earnings reports. Investors continued to assess upcoming corporate earnings while Tuesday saw another new 2-year high of 2.930% for the 10-year note.